Skip to content
← Full study record

NCT02255461 · OUTCOME

Number of Subjects With Objective Responses

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors · Source last updated 2021-03-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 2 years

What was measured

Objective responses included complete response (CR) and partial response (PR).

Analysis population: Patients who received at least one dose of palbociclib were included in the analysis. One patient in stratum II dose level 2 who withdrew prior to beginning protocol therapy was excluded.

Groups in this outcome

Stratum I, Dose Level 1 (50 mg/m2)

Less-heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Stratum I, Dose Level 2 (75 mg/m2)

Less-heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Stratum I, Dose Level 3 (95 mg/m2)

Less-heavily pre-treated patients received oral palbociclib daily at 95 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Stratum II, Dose Level 1 (50 mg/m2)

Heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Stratum II, Dose Level 2 (75mg/m2)

Heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Stratum I, Dose Level 1 (50 mg/m2)3
Stratum I, Dose Level 2 (75 mg/m2)12
Stratum I, Dose Level 3 (95 mg/m2)6
Stratum II, Dose Level 1 (50 mg/m2)4
Stratum II, Dose Level 2 (75mg/m2)9

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stratum I, Dose Level 1 (50 mg/m2)0Not reportedNot reportedNot reportedNot reported
Stratum I, Dose Level 2 (75 mg/m2)0Not reportedNot reportedNot reportedNot reported
Stratum I, Dose Level 3 (95 mg/m2)0Not reportedNot reportedNot reportedNot reported
Stratum II, Dose Level 1 (50 mg/m2)0Not reportedNot reportedNot reportedNot reported
Stratum II, Dose Level 2 (75mg/m2)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      12
    3. group Id
      OG002
      value
      6
    4. group Id
      OG003
      value
      4
    5. group Id
      OG004
      value
      9
    units
    Participants
description
Objective responses included complete response (CR) and partial response (PR).
groups
  1. description
    Less-heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Stratum I, Dose Level 1 (50 mg/m2)
  2. description
    Less-heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG001
    title
    Stratum I, Dose Level 2 (75 mg/m2)
  3. description
    Less-heavily pre-treated patients received oral palbociclib daily at 95 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG002
    title
    Stratum I, Dose Level 3 (95 mg/m2)
  4. description
    Heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG003
    title
    Stratum II, Dose Level 1 (50 mg/m2)
  5. description
    Heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG004
    title
    Stratum II, Dose Level 2 (75mg/m2)
param Type
COUNT_OF_PARTICIPANTS
population Description
Patients who received at least one dose of palbociclib were included in the analysis. One patient in stratum II dose level 2 who withdrew prior to beginning protocol therapy was excluded.
reporting Status
POSTED
time Frame
Up to 2 years
title
Number of Subjects With Objective Responses
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice